journal
https://read.qxmd.com/read/38865005/oral-pre-malignancy-an-update-on-novel-therapeutic-approaches
#1
REVIEW
Shorook Naara, Clara Andrews, Andrew Sikora, Michelle Williams, Mark Chambers, Jeffrey Myers, Moran Amit
PURPOSE OF REVIEW: This review aims to provide a comprehensive overview of the current advances in managing and preventing progression of oral potentially malignant disorders (OPMDs), focusing on their histological and clinicopathological features, and management. RECENT FINDINGS: Recent studies, including a multicenter cross-sectional study, have identified oral leukoplakia as the most prevalent form of OPMD, comprising over half of the cases examined. Advances in histological grading, specifically the World Health Organization's three-tier system (mild, moderate, and severe dysplasia), have significantly enhanced the accuracy of risk assessment for malignant transformation...
June 12, 2024: Current Oncology Reports
https://read.qxmd.com/read/38865004/frailty-and-cancer-prognosis
#2
REVIEW
Ana Patricia Navarrete-Reyes, Abigail Samayoa Mateos-Soria, Juan José Sánchez-Hernández, Juan Pablo Negrete-Najar
PURPOSE OF REVIEW: This review aims to summarize the current evidence regarding the prognostic role of frailty in older patients diagnosed with cancer and to explore the evidence regarding its prognostic implications in cancer survivors. RECENT FINDINGS: Frailty has been consistently associated with mortality/overall survival, postoperative complications, short- and long-term postoperative mortality, length of stay, among other adverse health-related outcomes in several oncological contexts...
June 12, 2024: Current Oncology Reports
https://read.qxmd.com/read/38861124/immunological-checkpoint-blockade-in-anal-squamous-cell-carcinoma-dramatic-responses-tempered-by-frequent-resistance
#3
REVIEW
Thejus Jayakrishnan, Devvrat Yadav, Brandon M Huffman, James M Cleary
PURPOSE OF REVIEW: Squamous cell carcinoma of the anus (SCCA) is an HPV-associated malignancy that has limited treatment options. Immunotherapy has expanded these options and here we review current and emerging immunotherapeutic approaches. RECENT FINDINGS: Multiple studies of single-agent anti-PD1/PD-L1 immunotherapy have demonstrated a modest response rate of approximately 10% to 15%. While a minority of patients (~5%) with SCCA experience durable complete responses, most advanced SCCAs are resistant to anti-PD1/PD-L1 monotherapy...
June 11, 2024: Current Oncology Reports
https://read.qxmd.com/read/38850505/toxicities-from-braf-and-mek-inhibitors-strategies-to-maximize-therapeutic-success
#4
REVIEW
Mike Wang, Ryan J Sullivan, Meghan J Mooradian
PURPOSE OF REVIEW: This report highlights several of the recent therapeutic advancements in the treatment of BRAF-mutant tumors, discusses the most common adverse events observed with BRAF-targeted agents, and suggests strategies to manage and mitigate treatment-related toxicities. RECENT FINDINGS: BRAF and MEK inhibitors represent a significant advancement in the treatment of BRAF-mutated malignancies with data across tumor types demonstrating the anti-tumor efficacy of dual MAPK inhibition...
June 8, 2024: Current Oncology Reports
https://read.qxmd.com/read/38847974/current-status-and-challenges-in-rare-genitourinary-cancer-research-and-future-directions
#5
REVIEW
Antonio Cigliola, Gagan Prakash, Roger Li, Karima Oualla, Gupta Shilpa, Ashish M Kamat, Jad Chahoud, Andrea Necchi, Philippe E Spiess
PURPOSE OF REVIEW: In contemporary urological practice, managing rare genitourinary (GU) malignancies presents significant challenges, necessitating a comprehensive understanding of their unique characteristics and tailored treatment approaches. RECENT FINDINGS: Rare GU malignancies, whether per se, variants of common histologies, or common tumors in uncommon locations, often lack widely available clinical guidelines. Consequently, treatment decisions are frequently based on empirical evidence, risking suboptimal outcomes...
June 7, 2024: Current Oncology Reports
https://read.qxmd.com/read/38847973/perioperative-blood-transfusions-and-cancer-progression-a-narrative-review
#6
REVIEW
Layal Abou Daher, Olivia Heppell, Ileana Lopez-Plaza, Carlos E Guerra-Londono
PURPOSE OF REVIEW: To examine the most recent evidence about known controversies on the effect of perioperative transfusion on cancer progression. RECENT FINDINGS: Laboratory evidence suggests that transfusion-related immunomodulation can be modified by blood management and storage practices, but it is likely of less intensity than the effect of the surgical stress response. Clinical evidence has questioned the independent effect of blood transfusion on cancer progression for some cancers but supported it for others...
June 7, 2024: Current Oncology Reports
https://read.qxmd.com/read/38842606/management-of-localized-melanoma-in-the-anti-pd-1-era
#7
REVIEW
Elan Novis, Alexander C J van Akkooi
PURPOSE OF REVIEW: The management of cutaneous melanoma has rapidly progressed over the past decade following the introduction of effective systemic therapies. Given the large number of recent clinical trials which have dramatically altered the management of these patients, an updated review of the current evidence regarding the management of localized melanoma is needed. RECENT FINDINGS: The role of effective systemic therapies in earlier stages (I-III) melanoma, both in adjuvant and neoadjuvant settings is rapidly changing the role of surgery in the management cutaneous melanoma, particularly regarding surgical safety margins for wide local excision (WLE), the role of sentinel lymph node biopsy (SLNB) and the extent of lymph node dissections...
June 6, 2024: Current Oncology Reports
https://read.qxmd.com/read/38842605/use-of-circulating-tumor-dna-to-guide-decision-making-in-adjuvant-colon-cancer
#8
REVIEW
Zachary Gottschalk, Stacey A Cohen
PURPOSE OF REVIEW: The use of circulating tumor DNA (ctDNA) assays to guide clinical decision-making in early-stage colon cancer is an area of rapidly advancing active research. With assays clinically available, clinicians must be informed how to best use this novel tool to treat patients. RECENT FINDINGS: Recent observational and prospective studies have suggested that ctDNA has potential to guide clinical decision-making in early-stage colon cancer by detecting minimal residual disease (MRD) and predicting recurrence risks...
June 6, 2024: Current Oncology Reports
https://read.qxmd.com/read/38837107/multiple-options-how-to-choose-therapy-in-frontline-metastatic-melanoma
#9
REVIEW
Lucy Boyce Kennedy, April K S Salama
PURPOSE OF REVIEW: Given the rapid development of multiple targeted and immune therapies for patients with advanced melanoma, it can be challenging to select a therapy based on currently available data. This review aims to provide an overview of frontline options for metastatic melanoma, with practical guidance for selecting a treatment regimen. RECENT FINDINGS: Recently reported data from randomized trials suggests that the majority of patients with unresectable melanoma should receive a PD-1 checkpoint inhibitor as part of their first line therapy, irrespective of BRAF mutation status...
June 5, 2024: Current Oncology Reports
https://read.qxmd.com/read/38837106/from-detection-to-cure-emerging-roles-for-urinary-tumor-dna-utdna-in-bladder-cancer
#10
REVIEW
Joshua A Linscott, Hiroko Miyagi, Prithvi B Murthy, Sijie Yao, G Daniel Grass, Aram Vosoughi, Hongzhi Xu, Xuefeng Wang, Xiaoqing Yu, Alice Yu, Logan Zemp, Scott M Gilbert, Michael A Poch, Wade J Sexton, Philippe E Spiess, Roger Li
PURPOSE OF REVIEW: This review sought to define the emerging roles of urinary tumor DNA (utDNA) for diagnosis, monitoring, and treatment of bladder cancer. Building from early landmark studies the focus is on recent studies, highlighting how utDNA could aid personalized care. RECENT FINDINGS: Recent research underscores the potential for utDNA to be the premiere biomarker in bladder cancer due to the constant interface between urine and tumor. Many studies find utDNA to be more informative than other biomarkers in bladder cancer, especially in early stages of disease...
June 5, 2024: Current Oncology Reports
https://read.qxmd.com/read/38822929/screening-and-testing-for-homologous-recombination-repair-deficiency-hrd-in-breast-cancer-an-overview-of-the-current-global-landscape
#11
REVIEW
Gordon R Daly, Sindhuja Naidoo, Mohammad Alabdulrahman, Jason McGrath, Gavin P Dowling, Maen M AlRawashdeh, Arnold D K Hill, Damir Varešlija, Leonie Young
PURPOSE OF REVIEW: Homologous recombination repair deficiency (HRD) increases breast cancer susceptibility and influences both prophylactic and active management of breast cancer. This review evaluates HRD testing and the therapeutic implications of HRD in a global context. RECENT FINDINGS: Ongoing research efforts have highlighted the importance of HRD beyond BRCA1/2 as a potential therapeutic target in breast cancer. However, despite the improved affordability of next-generation sequencing (NGS) and the discovery of PARP inhibitors, economic and geographical barriers in access to HRD testing and breast cancer screening do not allow all patients to benefit from the personalized treatment approach they provide...
June 1, 2024: Current Oncology Reports
https://read.qxmd.com/read/38822928/radiation-and-melanoma-where-are-we-now
#12
REVIEW
Roy Bliley, Adam Avant, Theresa M Medina, Ryan M Lanning
PURPOSE OF REVIEW: This review summarizes the current role of radiotherapy for the treatment of cutaneous melanoma in the definitive, adjuvant, and palliative settings, and combinations with immunotherapy and targeted therapies. RECENT FINDINGS: Definitive radiotherapy may be considered for lentigo maligna if surgery would be disfiguring. High risk, resected melanoma may be treated with adjuvant radiotherapy, but the role is poorly defined since the advent of effective systemic therapies...
June 1, 2024: Current Oncology Reports
https://read.qxmd.com/read/38814502/prevention-of-post-mastectomy-pain-syndrome-a-review-of-recent-literature-on-perioperative-interventions
#13
REVIEW
Rachel R Wu, Simon Katz, Jing Wang, Lisa V Doan
PURPOSE OF REVIEW: Up to 60% of breast cancer patients continue to experience pain three months or more after surgery, with 15 to 25% reporting moderate to severe pain. Post-mastectomy pain syndrome (PMPS) places a high burden on patients. We reviewed recent studies on perioperative interventions to prevent PMPS incidence and severity. RECENT FINDINGS: Recent studies on pharmacologic and regional anesthetic interventions were reviewed. Only nine of the twenty-three studies included reported a significant improvement in PMPS incidence and/or severity, sometimes with mixed results for similar interventions...
May 30, 2024: Current Oncology Reports
https://read.qxmd.com/read/38801612/an-annual-symposium-on-disparities-in-milwaukee-wi-with-a-2023-focus-on-older-adults-with-cancer
#14
REVIEW
Sailaja Kamaraju, June McKoy, Grant R Williams, Nikesha Gilmore, Christina Minami, Kathryn Bylow, Helena Rajalingam, Chandler S Cortina, Angela Beckert, Melinda Stolley, Dan Bullock, Razelle Kurzrock, Aminah Jatoi
PURPOSE OF REVIEW: Cancer-related inequities are prevalent in Wisconsin, with lower survival rates for breast, colorectal, and lung cancer patients from marginalized communities. This manuscript describes the ongoing efforts at the Medical College of Wisconsin and potential pathways of community engagement to promote education and awareness in reducing inequities in cancer care. RECENT FINDINGS: While some cancer inequities are related to aggressive disease biology, health-related social risks may be addressed through community-academic partnerships via an open dialogue between the community members and academic faculty...
May 27, 2024: Current Oncology Reports
https://read.qxmd.com/read/38789670/beyond-immune-checkpoint-inhibitors-emerging-targets-in-melanoma-therapy
#15
REVIEW
Andrew D Knight, Jason J Luke
PURPOSE OF REVIEW: This review provides a comprehensive update on recent advancements in melanoma treatment by highlighting promising therapeutics with an aim to increase awareness of novel interventions currently in development. RECENT FINDINGS: Over the last decade there has been considerable expansion of the previously available treatment options for patients with melanoma. In particular, novel immunotherapeutics have been developed to expand on the clinical advancements brought by BRAF targeting and immune checkpoint inhibitors...
May 25, 2024: Current Oncology Reports
https://read.qxmd.com/read/38789669/palliative-care-needs-of-patients-with-musculoskeletal-malignancies
#16
REVIEW
Clark Roth, Kurt Weiss
PURPOSE OF REVIEW: This review aims to assess the literature regarding current treatment options for the palliative care of patients with advanced musculoskeletal malignancies whether primary or metastatic. RECENT FINDINGS: The inclusion of specialized palliative care physicians, in conjunction with surgeons, medical oncologists, radiation oncologists, interventional radiologists, and mental health professionals, results in better control of end-of-life symptoms in both children and adults with terminal musculoskeletal malignancies...
May 24, 2024: Current Oncology Reports
https://read.qxmd.com/read/38780676/for-the-long-haul-management-of-long-term-survivors-after-melanoma-systemic-therapy
#17
REVIEW
Jordyn Silverstein, Neha Goyal, Katy K Tsai
PURPOSE OF REVIEW: This review summarizes the latest advancements in survivorship care for patients with advanced melanoma who received systemic therapy and emphasizes the areas where more research is needed. RECENT FINDINGS: Over the last decade there have been remarkable advances in the treatment of advanced and metastatic melanoma. Due to these novel treatments, including several immune checkpoint inhibitors and tyrosine kinase inhibitors, there are and will continue to be increasing numbers of long-term melanoma survivors who have been treated with systemic therapy...
May 23, 2024: Current Oncology Reports
https://read.qxmd.com/read/38780675/melanoma-in-pediatric-and-young-adult-patients
#18
REVIEW
Vernon K Sondak, Jane L Messina
PURPOSE OF REVIEW: Melanoma in younger individuals has different clinical presentations, histologic characteristics and prognosis from older patients. This review summarizes key differences and important new insights into pediatric and young adult melanoma, as well as recent evolutions in treatment. RECENT FINDINGS: Molecular techniques have improved the classification of melanocytic neoplasms, and are especially useful in the workup of the diagnostically challenging lesions frequent in this age group...
May 23, 2024: Current Oncology Reports
https://read.qxmd.com/read/38777980/robotic-surgery-for-head-and-neck-tumors-what-are-the-current-applications
#19
REVIEW
Po Ling Catherine Chan, Eddy Wai Yeung Wong, Jason Ying Kuen Chan
BACKGROUND: The journey from radical treatments to the precision of robotic surgery underscores a commitment to innovation and patient-centered care in the field of head and neck oncology. PURPOSE OF REVIEW: This article provides a comprehensive overview that not only informs but also stimulates ongoing discourse and investigation into the optimization of patient care through robotic surgery. The literature on current robotic applications within head and neck region was systematically reviewed...
May 23, 2024: Current Oncology Reports
https://read.qxmd.com/read/38777979/communication-between-caregivers-of-adults-with-cancer-and-healthcare-professionals-a-review-of-communication-experiences-associated-factors-outcomes-and-interventions
#20
REVIEW
Ying Wang, Christopher L Seplaki, Sally A Norton, AnnaLynn M Williams, Sindhuja Kadambi, Kah Poh Loh
PURPOSE OF REVIEW: Family/unpaid caregivers play an important role in cancer care. This review aims to summarize caregiver communication experiences with healthcare professionals (HCPs). RECENT FINDINGS: The Caregiver-Centered Communication model defines five core functions that HCPs should achieve when interacting with caregivers, including fostering relationships, exchanging information, recognizing and responding to caregiver emotions, aiding in decision making, and assisting in patient care management...
May 23, 2024: Current Oncology Reports
journal
journal
34702
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.